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Abstract
Background: A simple noninvasive model to predict obstructive coronary artery disease (OCAD) may promote risk
stratification and reduce the burden of coronary artery disease (CAD). This study aimed to develop pre-procedural,
noninvasive prediction models that better estimate the probability of OCAD among patients with suspected CAD
undergoing elective coronary angiography (CAG).
Methods: We included 1262 patients, who had reliable Framingham risk variable data, in a cohort without known
CAD from a prospective registry of patients referred for elective CAG. We investigated pre-procedural OCAD (≥50%
stenosis in at least one major coronary vessel based on CAG) predictors.
Results: A total of 945 (74.9%) participants had OCAD. The final modified Framingham scoring (MFS) model
consisted of anemia, high-sensitivity C-reactive protein, left ventricular ejection fraction, and five Framingham
factors (age, sex, total and high-density lipoprotein cholesterol, and hypertension). Bootstrap method (1000 times)
revealed that the model demonstrated a good discriminative power (c statistic, 0.729 ± 0.0225; 95% CI, 0.69–0.77).
MFS provided adequate goodness of fit (P = 0.43) and showed better performance than Framingham score (c
statistic, 0.703 vs. 0.521; P < 0.001) in predicting OCAD, thereby identifying patients with high risks for OCAD (risk
score ≥ 27) with ≥70% predictive value in 68.8% of subjects (range, 37.2–87.3% for low [≤17] and very high [≥41]
risk scores).
Conclusion: Our data suggested that the simple MFS risk stratification tool, which is available in most primary-level
clinics, showed good performance in estimating the probability of OCAD in relatively stable patients with suspected
CAD; nevertheless, further validation is needed.
Keywords: Prediction model, Obstructive coronary artery disease, Framingham risk
Introduction
A report from the national cardiovascular data registry of
the American College of Cardiology showed that only 41%
of patients undergoing elective coronary angiography
(CAG) are diagnosed as having obstructive coronary
artery disease (OCAD); hence, a better risk stratification
to increase pretest probability of coronary artery disease
(CAD) appears warranted [1]. A recent meta-analysis (33
studies, 120,548 participants) suggested that OCAD in
patients with acute coronary syndrome has a significantly
higher cardiovascular risk at baseline and a higher likeli-
hood of death or major cardiovascular events [2].
The classic risk stratification tool for CAD was the
Framingham score system, which predicts the 10-year
risk of coronary heart disease; however, the association
of Framingham score with plaque burden is less robust
[3, 4]. Although non-invasive diagnostic technology
advancements, such as stress testing and computed
tomography (CT) scanning adopted to increase the
pretest probability of CAD in most tertiary hospitals, are
available, high costs and unavailability limit their appli-
cation in daily clinical practice. Ibrahim et al. recently
established a new clinical and biomarker score with high
accuracy for predicting the presence of anatomically
significant CAD (≥70% stenosis), which included clinical
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variables (male sex and previous percutaneous coronary
intervention (PCI)) and four biomarkers (midkine,
adiponectin, apolipoprotein C-I, and kidney injury
molecule-1), among patients with known CAD (e.g., pa-
tients with previous acute myocardial infarctions (MI),
who had PCI, or who underwent coronary artery bypass
grafting (CABG)). However, whether this model could
predict CAD in patients presenting at primary-level
hospitals or clinics is unknown [5].
Therefore, this study aimed to establish a new simple
prediction model, including traditional Framingham risk
factors for OCAD, based on a continuously recruited at-
risk cohort from an observational database investigating
acute kidney injuries following elective CAG [6]. We
hypothesized that the addition of new contemporary
predictors to traditional Framingham risk factors could
increase the accuracy of predicting anatomically signifi-
cant CAD and, consequently, the novel model could be
used in a broader population with suspected CAD.
Methods
Study population
The study population was derived from a prospective
observational study PRECOMIN (NCT01400295)
database between January 2010 and December 2013.
The PRECOMIN study aimed at identifying the
optimal contrast volume to prevent contrast-induced
nephropathy among 3237 consecutive patients under-
going PCI/CAG, [6]. Patients who had previous PCI
or previous MI, CABG, acute MI, or emergent PCI
and those who lack total cholesterol (CHO) or high-
density lipoprotein cholesterol (HDL-C) data were
excluded (Additional file 1: Figure S1).
A total of 1262 patients without known CAD
undergoing elective CAG were included in the ana-
lysis. The Institutional Ethics Research Committee ap-
proved the study, and all patients provided written
informed consent.
Coronary angiography and data collection
CAG or PCI was performed according to the interven-
tional cardiologist’s preference, which is guided by insti-
tutional policy and practice. Baseline data, angiographic
characteristics, and medication data were prospectively
defined and have been reported in a previous study [6].
During CAG, the highest percent stenosis value within
each major coronary artery or their branches was re-
corded. High-sensitivity C reactive protein was tested
with a Beckman Coulter Immage immunobiochemistry
system (USA) using nephelometry (unit: mg/L). Left
ventricular ejection fraction was calculated by using the
biplane modified Simpson’s rule by Two-Dimensional
Echocardiography.
Definition
The primary endpoint of our study was OCAD, which
was defined as (≥50% stenosis by diameter in at least
one major coronary vessel based on CAG) [2]. Anemia
was defined according to the World Health Organization
criteria, i.e., baseline hematocrit value < 39% for men
and < 36% for women [7]. Hypertension was definite
present if the participant was under treatment with
antihypertensive medication or systolic≥140 mmHg or
diastolic ≥90 mmHg [3].
Statistical analysis
Continuous variables were compared with the t-test, and
categorical variables were compared with the chi-square
test or Fisher exact test, as appropriate. A logistic regression
model was developed to predict OCAD in the PRECOMIN
substudy. Significant predictors from the univariate analysis
and non-significant variables with potential clinical rele-
vance, including traditional Framingham risk factors, were
evaluated as candidate factors (age, sex, smoking status,
diabetes, CHO, high-density lipoprotein cholesterol [HDL-
C], hypertension, baseline systolic blood pressure, and
diastolic blood pressure, high-sensitivity C reactive protein
[hs-CRP],left ventricular ejection fraction [LVEF], anemia,
weight, serum creatinine, serum albumin, uric acid,HbA1c,
Lp(a), blood urea nitrogen,) to determine their association
with OCAD in a multivariable model [3]. Collinearity and
interaction between variables were also evaluated. Back-
ward elimination approach was employed to create a re-
duced model by successively removing non-significant
covariates until all the remaining predictors (age, sex, CHO
and HDL-C, hypertension, smoke, anemia, hs-CRP and
LVEF) are statistically significant (P < 0.1). Then, we
manually investigated the contribution of the remaining
predictors to find out the final predictors including age, sex,
CHO and HDL-C, hypertension, anemia, hs-CRP, LVEF.
We used regression coefficients from the model to generate
point scores for predicting the probability of OCAD [8, 9].
The final prediction model was assessed using the area
under the receiver operating characteristic (ROC) curve
and concordance c-statistic for discriminative ability, and
the Hosmer–Lemeshow goodness-of-fit statistic for calibra-
tion using fifths of the fitted risk values [10]. Moreover, the
final model was tested by bootstrapping method (1000
times) to evaluate the stability of the c-statistics. We as-
sumed that missing data occurred randomly, depending on
the clinical variables and the CAG results. We performed
multiple imputations using Markov chain Monte Carlo
(MCMC) and fully conditional specification (FCS) [11–13].
Comparisons of baseline characteristics and OCAD inci-
dence between patients with and those without missing
values were performed [14, 15]. A P value < 0.05 was con-
sidered statistically significant in all tests. All analyses were
performed using SAS version 9.3 (SAS Institute, Cary, NC).
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Results
A total of 1262 patients with complete data were in-
cluded in the final analysis (Additional file 1: Figure S1).
The study subjects’ baseline characteristics, dichoto-
mized as a function of the presence or absence of signifi-
cant CAD, are detailed in Table 1. Numerous baseline
characteristics differed between patients with (945,
74.9%) and those without OCAD.
Final modified Framingham prediction model
The final modified Framingham prediction model con-
sisted of the following: anemia (odds ratio [OR], 1.556;
P = 0.0053), hs-CRP (OR, 1.029; P = 0.0006), LVEF (OR,
0.979; P = 0.075), and five Framingham factors (age, sex,
CHO and HDL-C, hypertension), and our model
equation was “F(y) = − 0.0468 + 0.0204(age) + 1.0961(gen-
der) + 0.5444(hypertension) + 0.0055(CHO)-0.0257(HDL-
C)-0.022(LVEF) + 0.5677(anemia) + 0.0254(hs-
CRP)”(Table 2).
Modified Framingham scoring (MFS) system
In the entire cohort, the independent OCAD predictors
were anemia, hs-CRP, and LVEF, while the Framingham
risk factors were age, sex, CHO and HDL-C, and hyper-
tension. Model fitting performed on the validation
cohort showed that the MFS model performed better
than the traditional Framingham model (Table 3).
Additionally, individual scores were subsequently
calculated for patients in the validation cohort, and the
results were expressed as a function of CAD presence.
Consequently, a bimodal score distribution was found
(Fig. 1), with higher OCAD prevalence in patients
with higher scores and lower OCAD prevalence in
those with lower scores. Moreover, a bimodal distri-
bution of OCAD score was noted in the validation
set (n = 683), with preponderance of patients with
significant CAD with higher scores (positive: subjects
with at least 1 coronary stenosis ≥50%; negative:
subjects without coronary stenosis ≥50%).
Validation by bootstrap method and comparison of risk
score
Bootstrap method (1000 times) revealed that the model
demonstrated a good discriminative power (c-statistic,
0.729 ± 0.0225; 95% CI, 0.69–0.77).
In addition, the MFS provided adequate goodness of
fit (P = 0.43). For the operating characteristics of the
OCAD algorithm across various scores, the MFS model
had a higher area under the ROC curve than the Fra-
mingham score (c-statistic, 0.703 vs. 0.521; P < 0.001);
similarly, the modified Framingham risk factors model
had a higher area under the ROC curve than the Fra-
mingham risk factors model (c-statistic, 0.719 vs. 0.693;
P = 0.059) (Table 3; Fig. 2).
Moreover, the score was divided into four categories
according to predicted risk (low risk score, ≤17; moder-
ate risk score, 18–26; high risk score, 27–41; and very
high risk score, ≥42), which allowed identifying patients
with high risk for OCAD (risk score ≥ 27) with ≥70%
predictive value in 68.8% of subjects (range, 37.2–87.3%
for a low [≤17] and very high [≥41] risk score) (Fig. 3).
The predicted risk of CIN in the validation set is pre-
sented in parallel to the observed OCAD prevalence in
each risk group (Fig. 4).
Comparison between patients with missing data and
those with complete data
Most of the baseline characteristics were similar between
patients with missing data (n = 579) and those with
complete data (n = 683). The missing data in the final
model included gender, hypertension, smoking, CHO
and HDL-C, and LVEF. Patients with missing data were
younger and had lower hs-CRP level, systolic BP, and
rate of anemia than patients with complete data. No sig-
nificant difference in OCAD incidence (73.40 vs. 76.13%;
P = 0.2648) was noted (Additional file 2: Table S1).
Comparison of patients with complete, MCMC, and FCS
imputation data
We performed imputations of clinical variables and
CAG results for 100 times using MCMC and FCS.
Multivariate logistic regression and ROC curve were an-
alyzed for the final modified Framingham model using
complete and imputation data, and we found similar re-
sults, including ORs for predictor models and c-statistic
by ROC analysis (0.719, 0.712, 0.711) (Additional file 3:
Table S2 and Additional file 4: Table S3).
Discussion
In this study, Framingham risk score showed lower
discrimination for OCAD prevalence in patients with-
out known CAD undergoing elective CAG, whereas
our new simple MFS model showed better perform-
ance in estimating the pretest probability of OCAD
and identified more than two thirds of patients at
high risk for OCAD.
Framingham risk score including traditional risk factors,
which is the classic CAD risk-prediction model, showed
less association with OCAD in the present study, which is
consistent with a previous Canadian study that investi-
gated the association of Framingham risk score with com-
puted tomography angiography (CTA) measures of
coronary atherosclerosis. Coronary atherosclerosis was
present in 63.5% of the patients, which suggested a high
prevalence similar to that in our study (74.9% of OCAD).
Nevertheless, OCAD was diagnosed using CAG in our
study, which may have more accuracy and significance for
clinical decision than CTA [4].
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Our simple modified Framingham risk score (FRS)
might outperform FRS by ROC analysis, while we could
not further calculate the net reclassification improvement
to show how much improvement by using modified FRS
to predict OCAD. Because FRS was to predict the 10-year
risk of CAD, whose endpoint rate was lower than 15%,
Table 1 Baseline characteristics of patients without and those with obstructive coronary artery disease
Variables No (%) of patients with available data Subjects without
coronary stenosis
≥50%(n = 317)
Subjects with
coronary stenosis
≥50% (n = 945)
P value
Demographic
Age 1262(100) 62.0 ± 10.4 64.2 ± 10.2 < 0.001
Gender, men 1262(100) 181(57.1%) 693(73.3%) < 0.001
Signs and measurement
Heart rate, beats/min 1261(99.9) 73.4 ± 11.3 72.9 ± 11.9 0.49
Systolic BP, mm Hg 1262(100) 131.9 ± 17.9 132.7 ± 18.6 0.54
Diastolic BP, mm Hg 1262(100) 78.3 ± 12 77.5 ± 11.6 0.32
Weight, kg 1257(99.6) 63.5 ± 9.5 65.2 ± 10.9 0.01
Medical history
Smoking 1262 (100) 80(26.2%) 347 (36.7%) < 0.001
Hypertension 1262(100) 152(48.0%) 615 (65.1%) < 0.001
Congestive heart failure 1262(100) 19(6.5%) 79 (8.4%) 0.29
Diabetes mellitus 1260(99.8) 51(16.1%) 259 (27.5%) < 0.001
Hyperlipidemia 1262(100) 42(13.3%) 144 (15.2%) 0.75
Anemia 1262(100) 79(25.2%) 349 (37.5%) < 0.001
Medications
ACEI/ARB 1262(100) 240(75.7%) 864(89.5%) < 0.001
Diuretics 1261(99.9) 36(11.4%) 91(9.6%) 0.38
β-blocker 1262(100) 244(76.9%) 853(90.0%) < 0.001
Statin 1262(100) 279 (88.0%) 912(96.5%) < 0.001
Calcium-channel blocker 1259(99.8) 60(19.0%) 198(21.0%) 0.44
Physical examination
LVEF, % 1013(80.3) 64.6 ± 11 61.4 ± 11.9 < 0.001
Laboratory measures
Total cholesterol, mg/dl 1262(100) 168.2 ± 38.8 172.6 ± 64.6 0.15
HDL-C,mg/dl 1262(100) 40 ± 10.8 36.8 ± 10.3 < 0.001
Triglyceride, μmol/l 1262(100) 2.3 ± 11.8 1.6 ± 1.4 0.27
LDL cholesterol, μmol/l 1262(100) 2.5 ± 0.8 2.6 ± 0.9 0.19
Lp (a), μmol/l 1081(85.7) 211.4 ± 231.1 287.2 ± 311.4 < 0.001
Blood urea nitrogen, mg/dl 1246(98.7) 4.7 ± 1.6 5.2 ± 2.3 < 0.001
Serum Creatinine, μmol/l 1261(99.9) 78.0 ± 29.6 89.7 ± 50.7 < 0.001
Hemoglobin, g/ml 1246(100) 135.1 ± 15.1 133.3 ± 16.0 0.0929
Serum albumin, g/l 1220(96.7) 36.9 ± 4.1 36.1 ± 3.9 0.0035
Urine PH 1213(96.1) 5.9 ± 0.7 6.0 ± 0.7 0.48
HbA1c, % 1043(82.6) 6.3 ± 1.1 6.5 ± 1.2 0.006
Hs-CRP, mmol/l 849(67.3) 3.8 ± 5.7 6.6 ± 13.0 < 0.001
Uric acid, mmol/l 994(78.8) 364.6 ± 92.7 389.3 ± 102.5 < 0.001
B-type natriuretic peptide, pg/m 1041(82.5) 609.4 ± 2061.0 772.4 ± 2289.0 0.29
LVEF = left ventricular ejection fraction; ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; HDL-C = high-density lipoprotein
cholesterol; LDL-C = low-density lipoprotein-cholesterol; HbA1c = glycated hemoglobin; Hs-CRP = high-sensitivity C-reactive protein
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however, the modified FRS was to predict the OCAD with
higher rate (more than 50%) for patients with suspected
CAD, we could not find out ideal overlapping parts, ever
after adopting all the cut-off value of endpoint rate [3].
This study established a novel, simple risk stratification
method, which could be a useful tool in most primary-
level hospitals or clinics and requires no large equipment
or expensive examination in identifying patients with high
risk for OCAD. Genders et al. established prediction
models with a more accurate estimation of the pretest
probability of OCAD in lower prevalence populations
than that of the Duke clinical score, which is recom-
mended by an American College of Cardiology guideline.
However, to improve the model, coronary calcium score
by CT scanning and classification of chest pain symptoms
(i.e., typical, atypical, or non-specific) are necessary, which
requires medical knowledge and experience or equipment
and entails costs [16, 17].
Moreover, our results indicated that the use of MFS
model suggested the yield of testing (i.e., the proportion of
individuals referred for testing who have abnormal results)
among patients with a high pretest probability [18]. More
expensive or limited diagnostic tests in the risk stratifica-
tion in a large community population can be addressed by
the MFS model. In other word, the simple MFS model will
improve the precision of risk stratification for more physi-
cians, to increase invasive procedure among high risk
patients, but to reduce invasive procedure among low risk
patients.
For OCAD diagnosis, the modified Framingham score
had a final area under the ROC curve of 0.703 in the val-
idation set. Although the area under the ROC curves
was less than that of previous studies, the performance
of the MFS model was good [5, 18]. The small area
under the ROC curve in our study could be attributed to
the following: first, our study lacked more novel bio-
markers, which were selected from nearly one hundred
candidate variables [5]; second, the sample size was
smaller than that of previous studies [16, 18]; third, we
excluded subgroups with essential variables (e.g., PCI) or
missed some significant variables (e.g., types of chest
pain) [16].
One recent novel prediction score model in America
for significant CAD showed better performance (c-statis-
tic, 0.87 in the validation set); at the optimal cut-point,
the score was both highly sensitive (77%) and specific
(84%) for CAD diagnosis. The model included four
biomarkers (midkine, adiponectin, apolipoprotein C-I,
and kidney injury molecule-1). However, including these
biomarkers in the routine examination in primary-level
hospitals or clinics may not be suitable. In addition, the
model was established in patients with or without
known coronary disease and included previous PCI as a
predictor. Our simple model includes traditional risk
factors or routine examination without high cost. The
development setting was also different, i.e., our simple
model was based mostly on Chinese individuals; in the
American model, Whites.
The modified Framingham score has three additional
variables (i.e., hs-CRP, LVEF, and anemia), which could be
associated with both anatomically OCAD and coronary
events. A previous meta-analysis including 160,309 people
without a history of vascular disease suggested that CRP
concentration has continuous associations with the risk of
Table 2 Univariate analyses and multivariate associations between variables and obstructive coronary artery disease
Risk factors Univariate logistic regressiona Multivariate logistic regressionb
OR 95% CI P value OR 95% CI P value
Age, (per year) 1.11 1.04–1.18 < 0.01 1.02 1.00–1.04 0.05
Gender (male vs. female) 2.07 1.56–2.69 < 0.01 2.99 1.97–4.45 < 0.01
Hypertension (yes vs. no) 2.02 1.56–2.62 < 0.01 1.72 1.17–2.55 < 0.01
Anemia (yes vs. no) 1.78 1.33–2.37 < 0.01 1.76 1.14–2.72 < 0.01
LVEF (per %) 0.97 0.96–0.99 < 0.01 0.98 0.96–1.00 < 0.01
Hs-CRP (per mmol/l) 1.04 1.01–1.07 < 0.01 1.03 1.00–1.05 0.07
TC (per 10 mg/dl) 1.02 0.99–1.05 0.25 1.06 1.01–1.11 0.03
HDL-C (per mg/dl) 0.97 0.96–0.99 < 0.01 0.98 0.96–0.99 < 0.01
OR: odds ratio; CI: confidence interval; LVEF = left ventricular ejection fraction; Hs-CRP = high-sensitivity C-reactive protein; TC: total cholesterol; HDL-C = high-dens-
ity lipoprotein cholesterol
aUnivariate logistic regression analysis was performed in 1262 patients
bMultivariate logistic regression analysis was performed in 683 patients without missing data of the variables in the final model
Table 3 Modified Framingham risk factor and Framingham risk
factor model fitting
Model AUC AIC HLG P value
Modified Framingham risk factors 0.719 691 0.38 Reference
Framingham risk factors 0.693 705 0.35 0.059
Modified Framingham score 0.703 689 0.43 Reference
Framingham score 0.521 753 0.03 < 0.001
AUC: area under the curve; AIC: Akaike information criterion; HLG: Hosmer and
Lemeshow goodness-of-fit test
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CAD, ischemic stroke, vascular mortality, and death from
several cancers and lung diseases that are each of broadly
similar size [19]. A Japanese observational study with a
median follow-up period of 6.5 years showed that hs-CRP
was associated with higher incidence of major adverse
cardiac events or all-cause mortality in patients with
established CAD and undergoing PCI [20]. The Athero-
sclerosis Risk in Communities (ARIC) study, which
included 14,410 subjects (between 45 and 64 years) with-
out CVD and had a follow-up duration of 6.1 years,
showed that anemia is an independent risk factor for CVD
outcomes [21]. Another recent cohort study of outpatients
with stable CAD (21,829 with baseline hemoglobin levels)
showed that anemia is a powerful predictor of cardiovas-
cular and non-cardiovascular mortality [22]. Our study
may be the first to identify anemia as a CAD predictor. A
prospective study including 100 diagnostic coronary
catheterization candidates found that the overall accuracy
of akinesia/hypokinesia and LVEF < 55% in predicting ab-
normal CAG (≥50% stenosis) was poor [23]. Another
study on 182 patients undergoing exercise Tl-201 gated
single-photon emission computed tomography suggested
that worsening of the LVEF during exercise has the poten-
tial to detect multivessel CAD among patients without
multivessel patterns of reversible defects [24]. In our
study, the LVEF measured by average echo could also be a
CAD predictor. The predictive value of two new simple
predictors (LVEF and anemia) needs further external val-
idation in larger studies. Similarly, the new simple score
model also requires further evaluation in relation to risk
stratification. In addition, we would investigate the risk
factors of dangerous culprit lesions with culprit plaque
rupture (CPR) and thin-cap fibro-atheroma (TCFA), such
as hypertension, advanced ages, diabetes mellitus or
hyperlipidemia, which were evaluated by optical coher-
ence tomography (OCT) or intravenous ultrasound
(IVUS) in the futures [25].
Limitations
Our study has several limitations. First, our study adds
significant information to the current literature on
Fig. 1 Bimodal Modified Framingham scoring (MFS) distribution
Fig. 2 Receiver operating characteristic curve
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pretest probability of OCAD for stable patients without
known CAD; however, this is a single-center prospective
observational study with a limited sample size. Second,
angina types (e.g., classification of chest pain symptoms:
typical, atypical, or non-specific) were not considered;
thus, the accuracy of the OCAD risk model may have
been affected. Thirdly, some bias in patient selection es-
pecially in CAG possibly existed; cardiologists tended to
recruit patients with more baseline risk factors but with
a stable condition for elective CAG. Thus, our findings
may not be applicable to patients with low risk for
OCAD or with emergent conditions. Fourthly, our study
only focused on the anatomical result of angiography
without kind of plaque evaluated with imaging (OCTs or
IVUS), such as culprit plaque rupture (CPR) and thin-
cap fibro-atheroma (TCFA), which could trigger acute
coronary syndrome (ACS). Lastly, the high loss of
follow-up rate possibly affected the quality of long-term
prognosis and the predictive value of the modified
Framingham score.
Fig. 3 OCAD prevalence according to modified Framingham score
Fig. 4 Scheme to define OCAD risk score
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Conclusion
Our data suggested that the simple MFS risk stratification
tool, which is available in most primary-level hospitals or
clinics, showed good performance in estimating the pre-
test probability of OCAD and identified more than two
thirds of relatively stable patients with suspected CAD at
high risk for OCAD. Nevertheless, further external valid-
ation in larger studies is warranted.
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